Last updated: 11/04/2018 06:02:50
A Phase IIa Study Of Men And Post-Menopausal Women With A Fractured Distal Radius
EudraCT ID
EU CT Number
Not applicable
Trial status
Other
Other
Trial overview
Official title: A Proof-of-Concept Study Of SB-751689 In Men And Post-menopausal Women With A Fractured Distal Radius
Trial description: This is a study designed to test the safety and effectiveness of SB-751689 in the treatment of a distal radius fracture in post-menopausal women and men in comparison to placebo to determine if healing time of the fracture can be decreased.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:
Time to radiographic fracture healing
Timeframe: Up to Week 16
Secondary outcomes:
Number of participants with presence and/or absence of pain and swelling at each visit
Timeframe: Up to Week 16
Range-of-motion (ROM) over time as measured in flexion, extension, ulnar deviation, radial deviation, pronation and supination
Timeframe: Up to Week 16
Time until cast removal
Timeframe: Up to Week 16
Change from Baseline to Week 6 in 24-hour urine calcium concentrations
Timeframe: Baseline (Day 0) and Week 6
Percent change from Baseline to Week 6 and Week 12 of serum cross-linked C-terminal telopeptide alpha 1 chain of type 1 collagen (CTX)
Timeframe: Baseline (Day 0) and Week 6, 12
Percent change from Baseline to Week 6 and Week 12 of procollagen type 1 N propeptide (P1NP), bone specific alkaline phosphatase (BSAP) and osteocalcin (OC) concentrations
Timeframe: Baseline (Day 0) and Week 6, 12
Grip strength injured and uninjured at Baseline and Weeks 2, 4, 6, 8, 12 and Follow-up
Timeframe: Up to Week 16
Grip Strength Ratio of Injured/Uninjured at Baseline and Weeks 2, 4, 6, 8, 12 and Follow-up
Timeframe: Up to Week 16
Short form-36 questionnaire (SF-36) total and sub-scores at Baseline and Weeks 4, 8, 12 and follow-up percent of post treatment value over time
Timeframe: Up to Week 16
Change from Baseline in disabilities of the arm, shoulder and hand questionnaire (DASH) scores and sub-scores at Baseline and Weeks 6, 12 and follow-up percent of post treatment value over time
Timeframe: Baseline (Day 0) and Week 6, 12, 16
Number of participants with cortical bridging as assessed by computed tomography (CT) scan at Week 6
Timeframe: Up to Week 6
Number of participants with endosteal healing as assess by CT scan at Week 6
Timeframe: Up to Week 6
Interventions:
Enrollment:
85
Primary completion date:
2008-04-12
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Fracture Healing
Product
ronacaleret
Collaborators
Not applicable
Study date(s)
September 2007 to December 2008
Type
Interventional
Phase
2
Participation criteria
Sex
Female & Male
Age
35 - 80 years
Accepts healthy volunteers
No
- fracture/broken distal radius bone
- conservative treatment including closed reduction and immobilization device
- fracture occurred within 5 days of injury
- all AO B- and C-type
Inclusion and exclusion criteria
Inclusion criteria:
- fracture/broken distal radius bone conservative treatment including closed reduction and immobilization device men (>35 years <80) post-menopausal women (<80 yr) Full In/Ex crit. and EPs as per Amendment 1, dated 7 Feb 08 Subject is willing and able to provide written informed consent Unilateral, extra-articular distal radius fractures AO/ASIF types 23-A2 and 23-A3 are permissible. (Arbeitsgemeinschaft für Osteosynthesefragen [AO]/ Association for the Study of Internal Fixation [ASIF]). Multiple fractures of bones, other than the limb with the distal radius fracture, are permissible if the subject can perform the protocol-required procedures. Received conservative treatment of the distal radius fracture, including closed reduction and immobilization device (such as cast, splint, or brace) Ambulatory male and female subjects aged ≥35 to <80 years of age who have sustained a closed, unilateral, fracture of the distal radius no more than 5 days prior to randomization. Females of non child-bearing potential defined as: >1 year postmenopausal, which can be >1 year of spontaneous amenorrhea or >1 year post surgical bilateral oophorectomy. Use follicle stimulating hormone [FSH] levels >40mIU/mL to confirm surgical postmenopausal status, where bilateral oophorectomy status is uncertain. Females of child-bearing potential must have a negative urine bhCG pregnancy test at the Screening visit and agree to practice acceptable highly effective methods of birth control throughout the duration of the study. Highly effective birth control methods include those preventative measures taken to avoid pregnancy that have a failure rate of less than 1% per year. Subject who, in the opinion of the investigator, is willing and able to comply with the requirements of the protocol, including ability to understand patient reported outcomes (PRO) questionnaires
Exclusion criteria:
- fracture occurred within 5 days of injury all AO B- and C-type prior fracture of the same wrist placement of hardware (pins and plates) diseases affecting bone metabolism inflammatory joint disease an increased risk of osteosarcoma malignant disease diagnosed within the previous 5 years (except resected basal cell cancer) past or current history of liver disease or known hepatic or biliary abnormalities treatment with fluoride (dose greater than 10 mg/day) within the previous 5 years for osteoporosis limitations of prior treatment with an oral bisphosphonate Any treatment of a fractured distal radius that occurred more than 5 days after the fracture sustaining injury All B- and C-type fractures (intra-articular) according to AO Fracture classification or any distal radius fracture that would likely require open reduction and internal fixation. All additional fractures in the limb (including hand and humerus) with the distal radial fracture are excluded. Any fracture of the contralateral upper or lower arm, wrist or hand that would interfere with obtaining measurements on the dynamometer are excluded. Pathological (tumor-related) fractures Prior fracture of the same wrist as an adult Hardware including pins or plates in the wrist (either prior or current injury) History of or concurrent synovial pseudoarthrosis, congenital pseudoarthrosis, or active osteomyelitis History or concurrent diseases affecting bone metabolism (e.g., osteomalacia, hyperparathyroidism, etc.) History of skeletal immaturity Active disease or history of inflammatory joint disease (e.g., rheumatoid arthritis, lupus, psoriatic arthritis) that would interfere with imaging of the fracture Subjects receiving thyroid hormone replacement therapy should have thyroid stimulating hormone (TSH) levels measured.Subjects will be excluded if TSH levels are <0.1 or >10.0 mIU/L. However, subjects will not be excluded if TSH is in the range 0.1-4.5 mIU/L. If TSH is >4.5 to £10.0 mIU/L, measure T4 and exclude the subject only if the T4 is outside the normal range History of or active nephrolithiasis (kidney stones) Subjects at increased risk of osteosarcoma such as those with Paget’s disease of bone or history of any prior external beam or implant radiation therapy involving the skeleton Malignant disease diagnosed within the previous 5 years (except resected basal cell cancer) Active or history of malabsorption (e.g., history of celiac disease, irritable bowel syndrome, or inflammatory bowel disease) Note: Subjects are not excluded because of previous or active gastrointestinal disease (i.e., prior history of non-recurrent peptic ulcer disease). Symptoms of dyspepsia, or Gastroesophageal Reflux Disease (GERD) must be able to be controlled by occasional use (not more than 3 doses per week) of a histamine-2 receptor antagonist Past or current history of liver disease or known hepatic or biliary abnormalities (with the exception of previously documented diagnosis of Gilbert's syndrome) Drug or alcohol abuse (past or current) within the previous 12 months A history of risk factors for Torsades de Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome) A marked baseline prolongation of corrected QT interval (e.g., QTc interval ³450 msec on the Screening ECG corrected by either Bazett’s or Fridericia’s methodology) Surgical and medical conditions: Presence of the following conditions within 6 months prior to screening: myocardial infarction, coronary bypass surgery, coronary artery angioplasty, unstable angina, clinically evident congestive heart failure, cardiac pacemaker, or cerebrovascular accident: have currently known, suspected, or history of neurological diseases that affect the clinical assessments of healing; Cardiac arrhythmia: significant cardiac arrhythmias shown on screening ECG (as confirmed by eRT report), or a known or suspected history of significant cardiac arrhythmia's within 6 months prior to screening. i.e., pre-excitation syndromes, sinus pause >3 seconds, non-sustained ventricular tachycardia (³3 consecutive ectopic beats), sustained ventricular tachycardia (³30 consecutive ectopic beats), sustained supraventricular tachycardia (³30 consecutive ectopic beats), accessory pathway tachycardia, bradycardia (heart rate <50 beats per minute), atrial flutter, atrial fibrillation, ectopic pacemaker, sick sinus syndrome, atrioventricular block (second or third degree), or bundle branch block. Any clinically relevant biological abnormality found and/or volunteered at screening (other than those related to the disease under investigation) which, in the opinion of the investigator, is clinically significant and would preclude safe participation in this study [e.g., human immunodeficiency virus infection and significant mental illness] Inability to swallow whole tablets Any previous treatment with strontium ranelate or intravenous bisphosphonate Any previous treatment with an oral bisphosphonate as follows: any treatment within the last 6 months; ≥ 1 month cumulative treatment within the last 12 months; ≥ 3 months cumulative treatment within the past 2 years, or ≥ 2 years cumulative treatment within the past 5 years Treatment with fluoride (dose greater than 10mg/day) within the previous 5 years for osteoporosis Treatment with PTH, PTH analogues or similar anabolic agent for osteoporosis within the last 2 years Treatment with other drugs affecting bone metabolism within the last 6 months prior to screening:Chronic systemic corticosteroid (e.g., glucocorticoid, mineralocorticoid) treatment of no more than 2 intra-articular injections within the past year or use of oral, parenteral, or long-term, high-dose inhaled corticosteroids. Treatment with any topical corticosteroid will not exclude the subject from participating; Hormones (e.g., estrogens/"natural estrogen preparations" [except for nonsystemic vaginal treatment], 19-norprogestins, selective estrogen receptor modulators [SERMs] such as raloxifene, anabolic steroids/androgens such as dehydroepiandrosterone [DHEA] or its sulfated form [DHEAS], nandrolone, tibolone, active vitamin D analogs/metabolites that are prescribed for the treatment of osteoporosis or other conditions such as 1,25-dihydroxy vitamin D [calcitriol] or 1-alpha-hydroxyvitamin D3 [1-alpha hydroxycholecalciferol], calcitonin); Calcineurin inhibitors (e.g., cyclosporine, tacrolimus) or methotrexate Contraindications to therapy with calcium or vitamin D Any subject who received treatment with the macrolide antibiotics: clarithromycin, erythromycin, telithromycin, and troleandomycin within 2 days prior to the Baseline visit Administration of any investigational drug within 90 days preceding the first dose of the study medication Current treatment with potent P-glycoprotein and/or potent CYP3A inhibitors is prohibited: Diltiazem and verapamil; any oral azole antifungal (e.g., ketoconazole, itraconazole, fluconazole); Cyclosporine or oral tacrolimus; Ritonavir; Quinidine; Nefazodone Concomitant therapy with proton pump inhibitors (e.g., esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole) is prohibited. Daily, chronic use (>3 doses per week) of histamine-2 receptor antagonists (e.g., cimetidine, famotidine, nizatidine, and ranitidine) is prohibited. Antacids should not be administered within 2 hours (before or after) administration of study medication. Vitamin A in excess of 10,000 IU per day, heparin, lithium, or anticonvulsant medications (except benzodiazepines) Current therapy with digoxin Subjects taking daily, long-term (i.e., > 1 year) non-steroidal anti-inflammatory drugs (NSAIDs) for diseases such as inflammatory arthritis are excluded.  The use of low dose aspirin for prevention of heart disease is permitted. Short term use of NSAIDs is permitted for acute pain management but the use of alternative, non-NSAIDs is encouraged Total serum calcium levels outside the local laboratory reference range at the Screening visit Liver chemistries (aspartate aminotransferase [AST], alanine aminotransferase [ALT], or total bilirubin) exceeding 2‑fold the upper limit of the local laboratory reference range at the Screening visit Glomerular filtration rate (GFR) <35 mL/min as calculated by the Modification of Diet in Renal Disease (MDRD) equation as follows: GFR (mL/min/1.73 m2) = 186 x (Serum creatinine mg/dL)-1.154 x (Age)-0.203 x (0.742 if female) x (1.210 if African American) (conventional units) Women who are pregnant or breast-feeding are not allowed in the study. Females of child-bearing potential must have a negative urine bhCG pregnancy test at the Screening and Randomization visit and agree to practice acceptable highly effective methods of birth control through the duration of the study and for 4 weeks following the last dose of study medication. Highly effective birth control methods include those preventative measures taken to avoid pregnancy that have a failure rate of less than 1% per year.
Trial location(s)
Location
GSK Investigational Site
St Leonards, New South Wales, Australia, 2065
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Mar del Plata, Buenos Aires, Argentina
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Naciones Unidas 346, Córdova, Argentina, X5016KEH
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Ciudad autónoma de Buenos Aires, Buenos Aires, Argentina, C141AHN
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Geelong, Victoria, Australia, 3220
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Kogarah, New South Wales, Australia, 2217
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, C1117ABH
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Edinburgh, Midlothian, United Kingdom, EH16 4SA
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Ciudad Autónoma de Buenos Aires, Argentina, C1128AAF
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Rhyl, Flintshire, United Kingdom, LL18 5UJ
Status
Study Complete
Location
GSK Investigational Site
Buenos Aires, Buenos Aires, Argentina, 1425
Status
Study Complete
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Other
Actual primary completion date
2008-04-12
Actual study completion date
2008-04-12
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website